|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:approvalYear
|
2015
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01XC24
|
|
gptkbp:brand
|
gptkb:Darzalex_Faspro
gptkb:Darzalex
|
|
gptkbp:CASNumber
|
945721-28-8
|
|
gptkbp:combinationTherapy
|
gptkb:carfilzomib
gptkb:dexamethasone
gptkb:lenalidomide
gptkb:bortezomib
gptkb:pomalidomide
|
|
gptkbp:contraindication
|
hypersensitivity to daratumumab
|
|
gptkbp:developedBy
|
gptkb:Janssen_Biotech
|
|
gptkbp:form
|
solution for injection
solution for infusion
|
|
gptkbp:genericName
|
gptkb:daratumumab
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Darzalex
|
|
gptkbp:immunogenicity
|
low
|
|
gptkbp:indication
|
relapsed or refractory multiple myeloma
newly diagnosed multiple myeloma
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedIn
|
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
targets CD38 protein
|
|
gptkbp:molecularWeight
|
148 kDa
|
|
gptkbp:monoclonalAntibodyType
|
human IgG1 kappa
|
|
gptkbp:origin
|
recombinant DNA technology
|
|
gptkbp:pharmacokinetics
|
half-life 18 days
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:prescriptionRequired
|
https://www.darzalex.com/
|
|
gptkbp:PubChem_CID
|
DB09331
|
|
gptkbp:routeOfAdministration
|
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
fatigue
neutropenia
thrombocytopenia
infusion reactions
|
|
gptkbp:target
|
gptkb:CD38
|
|
gptkbp:UNII
|
82ZZY92M2I
|
|
gptkbp:usedFor
|
multiple myeloma
|
|
gptkbp:bfsParent
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
5
|